-
Original Article
-
- Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors
-
Yoon-Koo Kang1
, Min-Hee Ryu1, Yong Sang Hong1, Chang-Min Choi1, Tae Won Kim1, Baek-Yeol Ryoo1, Jeong Eun Kim1, John R. Weis2, Rachel Kingsford2, Cheol Hee Park3, Seong Jang3, Arlo McGinn3, Theresa L. Werner2, Sunil Sharma4
-
1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2University of Utah and Huntsman Cancer Institute, Salt Lake City, UT, USA
3Elevar Therapeutics, Fort Lee, NJ, USA
4Translational Genomics Research Institute, Phoenix, AZ, USA
- Corresponding author: Yoon-Koo Kang ,Tel: 82-2-3010-3230, Fax: 82-2-3010-8772, Email: ykkang@amc.seoul.kr
- Received: August 29, 2023; Accepted: January 17, 2024.
- Abstract
-
Fatal error: Call to undefined function abstract_title() in /home/virtual/e-crt/journal/m/journal/include.m_db.php on line 196
